CSIMarket Company Name, Ticker, Suppliers, else..
 
Fibrobiologics Inc   (NASDAQ: FBLG)
 
Price: $1.5300 $-0.08 -4.969%
Day's High: $1.6899000406265259 Week Perf: -10.53 %
Day's Low: $ 1.53 30 Day Perf: 33.04 %
Volume (M): 165,384 52 Wk High: $ 12.40
Volume (M$): $ 0 52 Wk Avg: $4.26
Open: $1.60 52 Wk Low: $0.60



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 6
 Employees 15
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Business Description


FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for chronic diseases such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential applications in human longevity. The company's leading product candidates include CYWC628, CYPS317, CYMS101, and CybroCell TM. Founded in 2021, FibroBiologics acquired intellectual property rights related to fibroblast technology from SpinalCyte LLC, operating as FibroGenesis.


   Company Address: 9350 Kirby Drive Houston 77054 TX
   Company Phone Number: 671-5150   Stock Exchange / Ticker: NASDAQ FBLG


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDX   -9.81%    
GERN   -10.93%    
LLY        2.13% 
OVID   -1.07%    
PFE   -1.57%    
SBFM   -6.14%    
• View Complete Report
   



Clinical Study

FibroBiologics Pioneering a Paradigm Shift in Cancer and Immune Therapy with Bone Marrow Organoids

Published Wed, Sep 10 2025 12:44 PM UTC

In the ever-evolving landscape of pharmaceutical sciences, innovation is the lifeblood that propels us toward groundbreaking treatments and therapies. FibroBiologics Inc., a trailblazer in regenerative medicine, has recently made significant strides with its avant-garde Bone Marrow Organoid platform, a development that stands to transform the approach to cancer and immune-re...
Product Service News

FibroBiologics Inc. Charts New Frontiers in Mitochondrial Modulation Amidst Financial Fluctuations,

Published Sat, Jun 14 2025 6:22 PM UTC

FibroBiologics Pioneers Mitochondrial Modulation: A New Horizon in Chronic Condition Therapeutics In the continuously evolving landscape of pharmaceutical science, innovation stands as the keystone to future medical breakthroughs. FibroBiologics Inc., a pioneering force in the industry, has recently taken a monumental step by filing a patent for a groundbreaking approach to ...
Clinical Study

Advancing Therapeutics FibroBiologics to Showcase Innovative Fibroblast-Based Approaches at The Cell & Gene Meeting...

Published Sat, Apr 12 2025 10:06 AM UTC

In an important development for the field of regenerative medicine, FibroBiologics, Inc. a clinical-stage biotechnology company, has announced its participation in The Cell & Gene Meeting on the Mediterranean, taking place from April 15-17, 2025, in Rome, Italy. The company s Chief Scientific Officer, Dr. Hamid Khoja, is set to present groundbreaking research focusing on the...
Stock Market Announcement

FibroBiologics Secures $5 Million Financing Tranche, Partners with Southern Star Research for Clinical Trials Amid Share Price Challenges,

Published Mon, Dec 30 2024 9:30 PM UTC

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing Amid Strategic CollaborationsHOUSTON, Dec. 30, 2024 FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company recognized for its innovative therapies targeting chronic diseases, has successfully closed the second $5 million tranche of a previously announced Standby Equity Purchase A...
Partnership

Southern Star Research to Collaborate with FibroBiologics as Clinical Research Organization in Australia

Published Thu, Sep 19 2024 1:31 PM UTC

: FibroBiologics, a pioneering company in the field of regenerative medicine, has recently engaged Southern Star Research as its Clinical Research Organization (CRO) in Australia. This partnership aims to facilitate the development of innovative therapies based on fibroblast technology. The engagement underscores the growing importance of strategic collaborations in advanc...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.07
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.59
Working Capital Ratio 2.64
Leverage Ratio (MRQ) 0.71
Total Debt to Equity 0.03
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.19 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.56 $
Book Value 0.74 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,209,267
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.